Novartis, Bayer among animal-health bidders

At least three drug companies--including Novartis and Boehringer Ingelheim--have made initial bids and remain in the race for animal health operations put on sale by Merck ($MRK) and Sanofi-Aventis ($SNY), sources tell Reuters. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.